Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab in diabetic peripheral neuropathy
NCT01087203Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Mar 2010
- Primary completion
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tanezumab in diabetic peripheral neuropathy (DPN), sponsored by Pfizer. Started Mar 2010; status: terminated.
02
Drugs
tanezumab
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT01087203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01087203.